IL17A and systemic lupus erythematosus: Overall, these genetic abnormalities are important contributors to the generation of the SLE “cytokine signature” milieu comprising mediators such as type I interferons, B-cell survival factors (BAFF), and several interleukins (IL-6, IL-12, IL-17, IL-23), all potential treatment targets (Figure 1 and Table 1).